Brainstorm Cell Therapeutics | BCLI - Equity Capital And Reserves


Brainstorm Cell Therapeutics reported $-11.6M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Alterity Therapeutics Limited AUD 36.21M 18.58M Dec/2025
Biogen USD 19.04B 194.3M Sep/2026
Brainstorm Cell Therapeutics USD -11.6M 588K Jun/2026
Cipla INR 353.96B 9.64B Sep/2026
Clal Biotechnology ILS 121.41M 4.62M Dec/2023
Compugen USD 88.73M 6.62M Jun/2026
CSL USD 18.66B 2.75B Dec/2025
Cytokinetics USD -321.17M 147.68M Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
Grifols EUR 6.21B 133.12M Dec/2025
Halozyme Therapeutics USD -55.24M 198.78M Sep/2026
Mesoblast USD 568.4M 6.28M Jun/2026